Thromb Haemost 2013; 109(05): 971-973 DOI: 10.1160/TH12-12-0908
Schattauer GmbH
Transient pseudothrombocytopenia associated with immune heparin-induced thrombocytopenia complicated by pulmonary embolism
Ann B. Zimrin
1
Department of Medicine, University of Maryland Greenebaum Cancer Center, Baltimore, Maryland, USA
,
Theodore E. Warkentin
2
Department of Pathology and Molecular Medicine, and Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada
› Author Affiliations
References
1
Warkentin TE,
Greinacher A,
Gruel Y.
et al.
on behalf of the Scientific, Standardization Committee of the International Society on Thrombosis, Haemostasis Laboratory testing for heparin-induced thrombocytopenia: a conceptual framework and implications for diagnosis. J Thromb Haemost 2011; 09: 2498-2500.
2
Greinacher A,
Farner B,
Kroll H.
et al.
Clinical features of heparin-induced thrombocytopenia including risk factors for thrombosis A retrospective analysis of 408 patients. Thromb Haemost 2005; 94: 132-135.
3
Bizzaro N.
EDTA-dependent pseudothrombocytopenia: A clinical and epidemiological study of 112 cases, with 10-year follow-up. Am J Hematol 1995; 50: 103-109.
4
Warkentin TE,
Kelton JG.
Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001; 344: 1286-1292.
5
Schwarzinger I,
Speiser W,
Lubenow N.
et al.
Heparin-platelet factor (PF) 4 antibodies in patients with pseudothrombocytopenia: coincidence or association?. Thromb Haemost 2000; 84: 1123-1124.
6
Martin-Toutain I,
Settegrana C,
Ankri A.
High levels of heparin-platelet factor 4 antibodies in patients with pseudothrombocytopenia: risk of misdiagnosis. Thromb Haemost 2009; 07: 1416-1418.
7
Balcik OS,
Akdeniz D,
Cipil H.
et al.
Heparin platelet factor 4 antibody positivity in pseudothrombocytopenia. Clin Appl Thromb Hemost 2012; 18: 92-95.